About AXSM

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsomes product candidate portfolio includes three clinical-stage candidates, AXS-02, AXS-05, and AXS-06. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD) and a Phase 2/3 trial in agitation in patients with Alzheimers disease (AD). AXS-02 is currently in Phase 3 trials in complex regional pain syndrome (CRPS) and knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs). A Phase 1 trial of AXS-06 has been completed. AXS-02, AXS-05, and AXS-06 are investigational drug products not approved by the FDA.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AXSM is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
DWAS Invesco DWA SmallCap Momentum ETF 254.5 M 2.545E+08 199 199 1.39% 0.01388 3.5 M 3501050
PTH Invesco DWA Healthcare Momentum ETF 145.5 M 1.455E+08 46 46 4.09% 0.04088 5.8 M 5849850
FHLC Fidelity MSCI Health Care Index ETF 1.5 B 1.5E+09 371 371 0.01% 0.000132782 205 K 204668
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.4 B 2.04474E+10 3,545 3545 0.0% 0 278 K 278429
IWC iShares Microcap ETF 858.7 M 8.58676E+08 1,430 1430 0.13% 0.0013 1.1 M 1074540